1. Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev 1953; 5:193-230.
2. Alvarez WC. Reverse peristalsis in the bowel, a precursor of vomiting. JAMA 1925; 85:1051-1054.
3. Borison HL, Wang SC. Further Studies on the Vomiting Center. Federation Proceedings 1950; 9:14-15.
4. Goldberg SL. The afferent paths of nerves involved in the vomiting reflex induced by distension of the isolated pyloric pouch. Am J Physiol 1931; 99:156-159.
5. Borison HL. Area postrema - chemoreceptor circumventricular organ of the medulla-oblongata. Prog Neurobiol 1989; 32:351-390.
6. Henzi I, Walder B, Tramèr MR. Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies. Br J Anaesth 1999; 83:761-771.
7. Kranke P, Morin AM, Roewer N, Eberhart LH. Dimenhydrinate for prophylaxis of postoperative nausea and vomiting: a meta-analysis of randomized
controlled trials. Acta Anaesthesiol Scand 2002; 46:238-44.
8. Kobrinsky NL. Regulation of nausea and vomiting in cancer chemotherapy. A review with emphasis on opiate mediators. Am J Pediatr Hematol Oncol 1988;
10:209-13.
9. Blancquaert JP, Lefebvre RA, Willems JL. Emetic and antiemetic effects of opioids in the dog. Eur J Pharmacol 1986; 128:143-50.
10. Henzi I, Walder B, Tramèr MR. Dexamethasone for the prevention of
postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg 2000; 90:186-194.
11. Tyers MB, Freeman AJ. Mechanism of the anti-emetic activity of 5-HT3 receptor antagonists. Oncology 1992; 49:263-8.
12. Leslie RA, Reynolds DJ, Andrews PL, Grahame-Smith DG, Davis CJ, Harvey JM. Evidence for presynaptic 5-hydroxytryptamine3 recognition sites on vagal afferent terminals in the brainstem of the ferret. Neuroscience 1990; 38:667-73.
13. van Wijk MG, Smalhout B. A postoperative analysis of the patient's view of anaesthesia in a Netherlands' teaching hospital. Anaesthesia 1990; 45:679-82.
14. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77:162-184.
15. Tramèr M, Moore A, McQuay H. Prevention of vomiting after paediatric strabismus surgery: a systematic review using the numbers-needed-to-treat
method. Br J Anaesth 1995; 75:556-561.
16. Palazzo MG, Strunin L. Anaesthesia and emesis. I: Etiology. Can Anaesth Soc J 1984; 31:178-87.
17. Tramèr MR. Systematic reviews in PONV therapy. In: Tramèr M (editor).
Evidence Based Resources in Anaesthesia and Analgesia 2nd edition. BMJ Books, London 2003; pp 108-116
18. Palazzo M, Evans R. Logistic regression analysis of fixed patient factors for postoperative sickness: a model for risk assessment. Br J Anaesth 1993; 70:135-40.
19. Lee M, Feldman M. Nausea and Vomiting. In: Sleisinger, MH and Fordtran, JS (editors). Gastrointestinal Disease: Pathophysiology, Diagnosis and
Management. 5th edition. W.B. Saunders Company Philadelphia, 1993. pp 509-523.
20. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, et al. On the receiving end. V: Patient perceptions of the side effects of cancer
chemotherapy in 1993. Ann Oncol 1996; 7:189-95.
21. Martin M. The severity and pattern of emesis following different cytotoxic agents. Oncology 1996; 53 Suppl 1:26-31.
22. Roila F, Del Favero A, Gralla RJ, Tonato M, Aapro MS, Andrews PLR, et al.
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the
Perugia consensus conference. Ann Oncol 1998; 9:811-819.
23. Anonymous. Sausville EA, Longo DL. Principles of Cancer Treatment. In:
Braunwald, E, Fauci, AS, Kasper, DL, Hauser, SL, Longo , DL, Jameson, JL (editors). Harrison's Principles of Internal Medicine 15th edition. McGraw-Hill, New York 2001; pp 530-47.
24. Garrick T, Mulvihill S, Buack S, Maeda-Hagiwara M, Tache Y.
Intracerebroventricular pressure inhibits gastric antral and duodenal
contractility but not acid secretion in conscious rabbits. Gastroenterology 1988;
95:26-31.
25. Kacker V, Gupta YK. An experimental model to study intracranial
hypertension-induced vomiting in conscious dogs. Methods Find Exp Clin Pharmacol 1996; 18:315-20.
26. Niemegeers CJ, Laduron PM. Pharmacology and biochemistry of haloperidol.
Proc R Soc Med 1976; 69 suppl 1:3-8.
27. Janssen PAJ, Niemegeers CJE. Chemistry and pharmacology of compounds related to 4-(4- hydroxy-4-phenyl-piperidino)-butyrophenone. 2. Inhibition of apomorphine vomiting in dogs. Arzneimittelforschung 1959; 9:765-767.
28. Holley FO, Magliozzi JR, Stanski DR, Lombrozo L, Hollister LE. Haloperidol kinetics after oral and intravenous doses. Clin Pharmacol Ther 1983; 33:477-84.
29. Midha KK, Chakraborty BS, Ganes DA, Hawes EM, Hubbard JW, Keegan DL, et al. Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol J Clin Psychopharmacol 1989; 9:98-104.
30. Forsman A, Ohman R. Applied pharmacokinetics of haloperidol in man. Curr Ther Res Clin Exp 1977; 21:396-411.
31. Forsman A, Folsch G, Larsson M, Ohman R. Metabolism of haloperidol in man.
Curr Ther Res Clin Exp 1977; 21:606-617.
32. Fang J, McKay G, Song J, Remillrd A, Li X, Midha K. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos 2001; 29:1638-43.
33. Forsman A, Ohman R. Pharmacokinetic studies on haloperidol in man. Curr Ther Res Clin Exp 1976; 20:319-336.
34. Beresford R, Ward A. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 1987; 33:31-49.
35. Stewart RB, Karas B, Springer PK. Haloperidol excretion in human-milk. Am J Psychiatry 1980; 137:849-850.
36. Ashton, H (editor). Brain Systems, Disorders, and Psychotropic Drugs. Oxford University Press, New York Oxford 1987.
37. Ungerstedt U. Striatal dopamine release after amphetamine or nerve
degeneration revealed by rotational behavior. Acta Physiol Scand 1971; Suppl.
367:49-68.
38. Lambert PA. Classification des neuroleptiques. In: Achaintre, A, Balvet, P, Beau-jard, M, Becache, A, Berthier, C, Brousolle, P, et al. (editors) Actualités de thérapeutique psychiatrique. Masson et Cie, Paris 1963.
39. Schorderet M, Calanca A. Neuroléptiques (antipsychotiques). In: Schorderet M (editor). Pharmacologie : Des concepts fondamentaux aux applications
thérapeutiques 3rd edition. Edition Frison-Roche, Paris 1998; pp397-413.
40. Fraser GL, Prato BS, Riker RR, Berthiaume D, Wilkins ML. Frequency, severity, and treatment of agitation in young versus elderly patients in the ICU.
Pharmacotherapy 2000; 20:75-82.
41. Niemegeers CJ, Janssen PA. In vivo interaction of haloperidol and apomorphine. Arch Int Pharmacodyn Ther 1978; 236:43-50.
42. Shields KG, Ballinger CM, Hathaway BN. Antiemetic effectiveness of
haloperidol in human volunteers challenged with apomorphine. Anesth Analg 1971; 50:1017-1024.
43. Reves GJ, Glass PSA, Lubarsky DA. Nonbarbiturate Intravenous Anesthetics.
In: Miller, RD (editor). Anaesthesia 4th edition. Churchill Livingstone, New York
1994; pp 274-276.
44. Atkinson RS, Rushman GB, Alfred Lee J. Pre- and Postoperative Medication. In:
Atkinson RS, Rushman GB, Alfred Lee J (editors). A Synopsis of Anaesthesia.
Wright, Bristol 1987; pp118-145.
45. Palazzo MG, Strunin L. Anaesthesia and emesis. II: Prevention and management. Can Anaesth Soc J 1984; 31:407-15.
46. Plotkin DA, Plotkin D, Okun R. Haloperidol in the treatment of nausea and vomiting due to cytotoxic drug administration. Curr Ther Res Clin Exp 1973;
15:599-602.
47. Frytak S, Moertel CG. Management of nausea and vomiting in the cancer patient. JAMA 1981; 245:393-396.
48. NNCN (National Comrephensive Cancer Network): Clinical Practice Guidelines in Oncology - v.1.2004. Accessed 30 March 2004 at:
www.nccn.org/physician_gls/PDF/antiemesis.pdf.
49. Rabow MW, Pantilat SZ, Brody RV. Care at the End of Life. In: Tierney, LM, McPhee, SJ, Papadakis, MA (editors). Current Medical Diagnosis & Treatment 2001 40th edition. Appleton & Lange / McGraw-Hill, New York 2002; pp109-120.
50. Mannix KA. Palliation of Nausea and Vomiting. In: Hanks GWC, MacDonald N, Doyle D (editors). Oxford Textbook of Palliative Medicine 2nd edition. Oxford
University Press, Oxford 1999; pp489-498.
51. Henzi I, Sonderegger J, Tramèr MR. Efficacy, dose-response, and adverse
effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anaesth 2000; 47:537-551.
52. Lischke V, Behne M, Doelken P, Schledt U, Probst S, Vettermann J. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994;
79:983-6.
53. FDA strengthens warning for droperidol. Accessed on 17 March 2004 at:
www.fda.gov/bbs/topics/ANSWERS/2001/ANS01123.html
54. Canada. Accessed 15 December 2002 at: www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/advisory/tpd/droperidol_e.html.
55. Reilly JG, Ayis SA, Jones SJ, Thomas SHL. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355:1048-1052.
56. Lawrence KR, Nasraway SA. Conduction disturbances associated with
administration of butyrophenone antipsychotics in the critically ill: a review of the litterature. Pharmacotherapy 1997; 17 :531-537.
57. White PF. Droperidol: a cost-effective antiemetic for over thirty years. Anesth Analg 2002; 95:789-90.
58. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the
QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;
354:1896-900.
59. L'Abbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987; 107:224-33.
60. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12.
61. Tramèr MR. A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part II. Recommendations for prevention and treatment, and research agenda. Acta Anaesthesiol Scand 2001;
45:14-19.
62. Hesketh PJ, Gralla RJ, du Bois A, Tonato M. Methodology of antiemetic trials:
response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer 1998; 6:221-7.
63. Morris JA Gardner MJ. Calculating confidence intervals for relative risk, odds ratio, and standardised ratio and rates. In: Gardner MJ, Altman DG (editors) Confidence Intervals and Statistical Guidelines 1st edition. British Medical Journal,
1995, pp50-63
64. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27:335-71.
65. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310:452-4.
66. Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
Anesthesiology 1997; 87:1277-89.
67. Barton MD, Libonati M, Cohen PJ. The use of haloperidol for treatment of postoperative nausea and vomiting - a double-blind placebo-controlled trial.
Anesthesiology 1975; 42:508-512.
68. Christman RS, Weinstein RA, Larose JB. Low-dose haloperidol as antiemetic treatment in gastrointestinal disorders: a double-blind study. Curr Ther Res 1974;
16:1171-1176.
69. Cole DR, Duffy DF. Haloperidol for radiation sickness: Control of associated nausea, vomiting, and anorexia. N Y State J Med 1974; 74:1558-1562.
70. Dyrberg V. Haloperidol (Serenase®) in the prevention of postoperative nausea
and vomting. Acta Anaesthesiol Scand 1962; 6:37-47.
71. Grunberg SM, Gala K, Lampenfeld M, Jamin D, Johnson K, Cariffe P, et al.
Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. J Clin Oncol 1984; 2:782-7.
72. Maggi U, Danieli G, Zatelli R. Rilievi sull'insorgena del vomito, sulle
modificazioni pressorie e sul tempo di risveglio in sogetti trattati nel decorso post-operatorio con un derivato del butirrofenone (haloperidol). Acta
Anaesthesiol 1964; 15 Suppl 4:159-170.
73. Neidhart JA, Gagen M, Young D, Wilson HE. Specific antiemetics for specific cancer chemotherapeutic agents: haloperidol versus benzquinamide. Cancer 1981; 47:1439-1443.
74. Neidhart JA, Gagen MM, Wilson HE, Young DC. Comparative trial of the antiemetic effects of THC and haloperidol. J Clin Pharmacol 1981; 21:38S-42S.
75. Robbins EL, Nagel JD. Haloperidol parenterally for treatment of vomiting and nausea from gastrointestinal disorders in a group of geriatric patients: double-blind, placebo-controlled study. J Am Geriatr Soc 1975; 23:38-41.
76. Saller R, Hellenbrecht D. Nutzen und Risiko von hochdosiertem Metoclopramid im Vergleich zu hochdosiertem Haloperidol oder
Triflupromazin bei Cisplatin-induziertem Erbrechen. Klin Wochenschr 1985;
63:428-432.
77. Silvey L, Carpenter-Jr JT, Wheeler RH, Lee J, Conolley C. A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. J Clin Oncol 1988; 6:1397-1400.
78. Tornetta FJ. Double-blind evaluation of haloperidol for antiemetic activity.
Anesth Analg 1972; 51:964-967.
79. Dannemiller FJ. A double-blind evaluation of the antiemetic properties of Haldol
in hospitalized patients following operative procedures. McNeil Laboratories Inc.
January 1974. Accessed 17 March 2004 at: www.hcuge.ch/anesthesie/data.htm
80. DeBakker A. A double-blind evaluation of the antiemetic properties of Haldol in
hospitalized patients following operative procedures (Trial A). McNeil
Laboratories Inc. January 1974. Accessed 17 March 2004 at:
www.hcuge.ch/anesthesie/data.htm
81. DeBakker A. A double-blind evaluation of the antiemetic properties of Haldol in
hospitalized patients following operative procedures (Trial B) McNeil
Laboratories Inc. January 1974. Accessed 17 March 2004 at:
www.hcuge.ch/anesthesie/data.htm
82. DeBakker A. A double-blind evaluation of the antiemetic properties of Haldol in
hospitalized patients following operative procedures. (Trial C) McNeil
Laboratories Inc. January 1974. Accessed 17 March 2004 at:
www.hcuge.ch/anesthesie/data.htm
83. Everett SF. A double-blind evaluation of the antiemetic properties of Haldol in
hospitalized and nonhospitalized patients with nausea and vomiting as a result of gastrointestinal disorders. McNeil Laboratories Inc. January 1974. Accessed
17 March 2004 at: www.hcuge.ch/anesthesie/data.htm
84. Leslie RE. A double-blind evaluation of the antiemetic properties of Haldol in
nonhospitalized patients with nausea and vomiting as a result of gastrointestinal disorders (Trial A). McNeil Laboratories Inc. January 1974. Accessed 17 March
2004 at: www.hcuge.ch/anesthesie/data.htm
85. Leslie RE. A double-blind evaluatioin of the antiemetic properties of Haldol in
nonhospitalized patients with nausea and vomiting as a result of gastrointestinal
disorders (Trial B). McNeil Laboratories Inc. January 1974. Accessed 17 March 2004 at: www.hcuge.ch/anesthesie/data.htm
86. Ritter R, Watson RL. A double-blind evaluation of the antiemetic properties of
Haldol in hospitalized patients following operative procedures. McNeil Laboratories Inc. January 1974. Accessed 17 March 2004 at:
www.hcuge.ch/anesthesie/data.htm
87. Kazemi-Kjellberg F, Henzi I, Tramèr MR. Treatment of established
postoperative nausea and vomiting: a quantitative systematic review. BMC Anesthesiol 2001; 1:2.
88. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158:1774-82.
89. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT.
Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;
58:1161-7.
90. Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, et al.
Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic
drugs: cohort study using administrative data. BMJ 2002; 325:1070.
91. Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81:238-40.
92. Perrault LP, Denault AY, Carrier M, Cartier R, Belisle S. Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery.
Can J Anaesth 2000; 47:251-4.
93. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right?
Interpreting zero numerators. JAMA 1983; 249:1743-5.
94. Wisely NA, Shipton EA. Long QT syndrome and anaesthesia. Eur J Anaesthesiol 2002; 19:853-9.
95. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT Statement.
JAMA 1996; 276:637-9.
96. Eberhart LH, Morin AM, Bothner U, Georgieff M. Droperidol and 5-HT3-receptor antagonists, alone or in combination, for prophylaxis of postoperative nausea and vomiting. A meta-analysis of randomised controlled trials. Acta Anaesthesiol Scand 2000; 44:1252-1257.
97. Tramèr MR, Walder B. Efficacy and adverse effects of prophylactic antiemetics
during patient- controlled analgesia therapy: a quantitative systematic review.
Anesth Analg 1999; 88:1354-1361.
98. Culebras X, Corpataux JB, Gaggero G, Tramèr MR. The antiemetic efficacy of droperidol added to morphine patient-controlled analgesia: a randomized,
controlled, multicenter dose-finding study. Anesth Analg 2003; 97:816-21.
7. Tables and figures
Table 1. Single-dose haloperidol regimens in surgery and gastrointestinal diseases.
Table 2. Haloperidol for chemo- and radiotherapy- related nausea and vomiting.
Figure 1. Flow chart of retrieved, excluded and analyzed reports.
Figure 2. Prevention of postoperative nausea and vomiting with parenteral single-dose
haloperidol regimens.
Figure 3. Treatment of established postoperative nausea and vomiting with parenteral
single-dose haloperidol regimens.
Figure 4. Treatment of nausea and vomiting related to gastrointestinal related diseases
with intramuscular single-dose haloperidol.